Company news

Novavax, Inc. news in 2026

Novavax, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights

November 5, 2026

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

October 29, 2026

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

October 29, 2026

Novavax to Participate in September Investor Conferences

September 2, 2026

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

August 28, 2026

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

August 6, 2026

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

Novavax to Participate in 2026 Jefferies Global Healthcare Conference

June 1, 2026

Novavax to Participate in BofA Securities 2026 Health Care Conference

May 7, 2026

Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

May 6, 2026

Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

April 29, 2026

Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

March 29, 2026

Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

February 25, 2026

Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

February 18, 2026

Novavax Announces Entering into a License Agreement with Pfizer

January 20, 2026

Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Calls in 2026

Decks in 2026